Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below:

	Abstract Title	Poster Presentation Details
NXP800	Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial	Session Title First-in-Human Phase I Clinical Trials 1 Session Date / Time April 8th, 1:30 - 5:00 PM
NXP800	Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800 - a new developmental agent for platinum-resistant ARID1A mutant ovarian cancer	Session Title Cell Cycle, Transcription Regulation, and Anticancer Drug Action Session Date / Time April 7th, 1:30 - 5:00 PM
NXP800	Discovery of ARID1A loss as a patient biomarker for NXP800 – a developmental activator of the integrated stress response (ISR) and inhibitor of the HSF1 pathway in ovarian cancer	Session Title Predictive Biomarkers 6 Session Date / Time April 9th, 1:30 - 5:00 PM
NXP800	A novel GCN2 kinase activator demonstrates therapeutic efficacy in preclinical PDX models of human cholangiocarcinoma	Session Title Novel Targets and Pathways Session Date / Time April 8th, 9:00 AM - 12:30 PM
NXP900	Src family kinase inhibition demonstrates antitumor activity in vitro and in patient-derived xenograft models of human cholangiocarcinoma	Session Title Kinase and Phosphatase Inhibitors 1 Session Date / Time April 7th, 1:30 - 5:00 PM
NXP900	NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors	Session Title